Andrew Portuguese
@AJPortuguese
Assistant Professor in BMT/IMTX at @FredHutch/@UWMedicine. Passionate about multiple myeloma. Views are mine.
Great group, great institution, great city. DM if interested! @fredhutch @UWMedicine
🚨 We’re recruiting! @fredhutch is seeking a clinician scholar in multiple myeloma — an incredible opportunity to join a world-class team, lead cutting-edge clinical research, and care for patients at a premier academic center. Outstanding environment. Unparalleled resources.…
Great @BloodCancerJnl RW data from US #MMsm consortium, led by @DimaDanai @leshune et al! BCMA bsAbs can work in BCMA-exposed. While we await better predictive tools, time & type of prior therapy matters: - ⬆️ PFS if > 9 months since prior BCMA - ⬇️ PFS if prior BCMA was bsAb
#Myeloma Paper of the Day: Patients w/ >8.7 mos between last exposure to prior BCMA-directed therapy & teclistamab have significantly improved median PFS w/ tec (8.1 mos, 95% CI: 4.6-11.7) vs. pts with <8.7 mos (2.5 ms, 95% CI: 1.1-5.7), p=0.001: pubmed.ncbi.nlm.nih.gov/40562770/. #mmsm
It’s love at first cite 😂
I am once again pitching my romantic comedy: - two academics start dating - discover they are each other's terrible reviewer - hijinks ensue Working title: Love is Double-Blind
Just out: Guidelines for testing and reporting cytogenetic results in myeloma @BloodCancerJnl #OpenAccess Bookmark! Allows you to incorporate latest IMS/IMWG high risk criteria in practice. @lbaughn @RahulBanerjeeMD @Rfonsi1 nature.com/articles/s4140…
Great job @Kennethjclim presenting @MayoCancerCare risk factor of IEC-nerve palsy & Parkinsonism #EHA25 #mmsm Hopefully we will learn soon from CARTITUDE trials & RWE across centers whether additional early mitigating strategies could reduce the risk further @IMFmyeloma
The Rock N Roll Division (#RnRD) performing at the @fredhutch faculty retreat. Rhiannon by @fleetwoodmac. @BruceClurman @huubgelderblom @kelleyrose99
CONGRESS | #EHA2025 | PRESENTATION Gurbakhash Kaur @GKaurMD, @MountSinaiNYC, shares the findings from the iMMagine-1 trial, which evaluates the safety and efficacy of anito-cel in R/R #multiplemyeloma (N=117). Anito-cel demonstrated deep and durable responses with ORR (per IMWG…
ATLAS Phase 3 study at #EHA2025 . Extended KRd as maintenance post-ASCT in NDMM led to prolonged and deep responses, in high-risk disease, as well as MRD positive and negative patients. Slightly higher rate of lung infections observed in KRd group. #mmsm
Plenary #3 #EHA2025 Very proud 🇦🇺 of @ALLGtrials randomized CAST trial Practice-changing study showing substantial reduction in GRFS, relapse-free survival & GvHD for PTCy in matched sibling donor allogeneic transplant Out in @NEJM nejm.org/doi/full/10.10… #bmtsm